Cipla enters into a licensing agreement with MSD to expand access to investigational oral therapeutic drug for COVID-19 treatment equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Centre made interim allocation of Tocilizumab to states
By IANS |
2 Views
New Delhi, April 28 : As limited stock of Tocilizumab is available in the country, the Centre has made interim allocation of injection to the states.
In letter dated April 27 to states, Joint Secretary, Department of Pharmaceuticals, Navdeep Rinwa Aand Rajiv Wadhawan wrote, The drug went out of stock in the country a few weeks ago due to a sudden surge in its demand because of a sharp rise in Covid-19 cases in the country in this month.
They further wrote that fresh limited stock of this drug has now been imported and is available with the lone marketer company Cipla Limited for marketing and distribution in the country.
Cipla to commercialise Molnupiravir for COVID-19 treatment
28 April 2021 | News Cipla will be permitted to manufacture, market and distribute Molnupiravir in India and more than 100 low and middle income countries
Source credit: Shutterstock
Cipla Limited announced that it has signed a non-exclusive licensing agreement with MSD a tradename of Merck & Co, Inc, Kenilworth, NJ, US for the manufacturing and distribution of Molnupiravir, the investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalised patients with confirmed COVID-19.
MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics. This agreement is a part of Cipla’s efforts to enhance global access to treatments for patients affected by the pandemic.
Tags »
To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.
“To advance a drug quickly and across the globe in all the countries where it is needed, you need the capacity of a company like Merck,” said George Painter, PhD, CEO of the non-profit Emory-owned DRIVE (Drug Innovation Ventures at Emory), at a media briefing Tuesday. “It’s gratifying to see how quickly they moved and how they’re getting this into the hands of people in India to meet this threat.”
Search jobs 20-Apr-2021 Ulcerative Colitis Treatment Market Complete Analytical Report for 2028 with Key Players- Sanofi Aventis Pharma India, Sun Pharmaceuticals Industries Ltd, Ranbaxy laboratories Inc, Sandoz Inc Ulcerative colitis is a chronic inflammatory disease that causes sores and inflammation in the innermost lining of large intestine and rectum. Ulcerative colitis causes ulcers, bleeding, mucus and pus. The disease is difficult to diagnose as its symptoms mimic other intestinal disorders such as irritable bowel syndrome (IBS). The main symptoms of ulcerative colitis include diarrhea, rectal bleeding, belly pain, etc. People with the Jewish heritage have higher incidence of this type of disease.